Q-omics provides the consensus-scored FOXQ1 profile across patient tissues and cancer cell-line models. FOXQ1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, FOXQ1 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, FOXQ1 RNA expression shows 14,280 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, COAD, and TGCT as cancer lineages where FOXQ1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FOXQ1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FOXQ1 survival associations across molecular data types. FOXQ1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FOXQ1 RNA expression–survival associations across cancer types. High FOXQ1 expression shows unfavorable associations in SKCM, CESC and PAAD, but favorable associations in KIRP, UCEC and GBM. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for FOXQ1 RNA expression.
This table summarizes FOXQ1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for FOXQ1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FOXQ1 shows lower tumor expression in KICH and KIRC and higher tumor expression in COAD, THCA, LIHC and READ. The COAD box plot shows higher FOXQ1 RNA expression in tumor versus normal tissue (log2 FC = +5.850, t-test p < 0.001).
This table shows molecular features associated with FOXQ1 in patient tissues and cancer cell lines. In patient samples, FOXQ1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, FOXQ1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LARGE_INTESTINE.
